TY - JOUR
T1 - Real-world study of the concomitant use of biphasic insulin as part 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes
AU - Davies, Melanie
AU - Alibegovic, Amra Ciric
AU - Anil, Gayathri
AU - Braae, Uffe Christian
AU - Jensen, Anders Boeck
AU - Nordsborg, Rikke Baastrup
N1 - Publisher Copyright:
© 2024 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
PY - 2024/5
Y1 - 2024/5
N2 - Aims: Combining insulin with a glucagon-like peptide-1 receptor agonist (GLP-1RA) to treat type 2 diabetes (T2D) is common. While many studies have investigated concomitant therapy with basal insulin+GLP-1RA, few have reported on premixed insulin+GLP-1RA. We aimed to address this gap using data from the Clinical Practice Research Datalink Aurum database in England. Methods: This retrospective cohort study with propensity score matching assessed glycaemic levels and other clinical outcomes in people with T2D, comparing biphasic insulin aspart 30/70 (BIAsp 30) + GLP-1RA with basal insulin (insulin detemir/glargine U100) + GLP-1RA (from 2006 to 2021). Results: In total, 4770 eligible people were identified; 1511 had a BIAsp 30 + GLP-1RA regimen and were propensity score-matched to an equal number receiving basal+GLP-1RA. There was no significant difference in glycated haemoglobin (HbA1c) reduction between cohorts at 6 months (p = 0.15), with a decrease of −1.07 (95% CI: −1.16; −0.98) %-points (−11.7 mmol/mol [95% CI: −12.7; –10.7]) in the BIAsp 30 + GLP-1RA cohort, versus −0.97 (95% CI: −1.07; −0.88) %-points (−10.6 mmol/mol [95% CI: −11.7; –9.6]) in the basal+GLP-1RA cohort. Body mass index (BMI) decreased by −0.35 kg/m2 (95% CI: −0.52;−0.18) at 6 months with BIAsp 30 + GLP-1RA, versus −0.72 kg/m2 (95% CI: −0.90;−0.54) with basal+GLP-1RA (p = 0.003). BMI was influenced by the initiation sequence of GLP-1RA in relation to insulin (p < 0.0001). Hypoglycaemia rates were low and not significantly different between cohorts. Conclusions: Combining BIAsp 30 + GLP-1RA provides glycaemic control with no significant difference to that of propensity score-matched people receiving basal insulin+GLP-1RA, with no increase in hypoglycaemia risk or weight gain.
AB - Aims: Combining insulin with a glucagon-like peptide-1 receptor agonist (GLP-1RA) to treat type 2 diabetes (T2D) is common. While many studies have investigated concomitant therapy with basal insulin+GLP-1RA, few have reported on premixed insulin+GLP-1RA. We aimed to address this gap using data from the Clinical Practice Research Datalink Aurum database in England. Methods: This retrospective cohort study with propensity score matching assessed glycaemic levels and other clinical outcomes in people with T2D, comparing biphasic insulin aspart 30/70 (BIAsp 30) + GLP-1RA with basal insulin (insulin detemir/glargine U100) + GLP-1RA (from 2006 to 2021). Results: In total, 4770 eligible people were identified; 1511 had a BIAsp 30 + GLP-1RA regimen and were propensity score-matched to an equal number receiving basal+GLP-1RA. There was no significant difference in glycated haemoglobin (HbA1c) reduction between cohorts at 6 months (p = 0.15), with a decrease of −1.07 (95% CI: −1.16; −0.98) %-points (−11.7 mmol/mol [95% CI: −12.7; –10.7]) in the BIAsp 30 + GLP-1RA cohort, versus −0.97 (95% CI: −1.07; −0.88) %-points (−10.6 mmol/mol [95% CI: −11.7; –9.6]) in the basal+GLP-1RA cohort. Body mass index (BMI) decreased by −0.35 kg/m2 (95% CI: −0.52;−0.18) at 6 months with BIAsp 30 + GLP-1RA, versus −0.72 kg/m2 (95% CI: −0.90;−0.54) with basal+GLP-1RA (p = 0.003). BMI was influenced by the initiation sequence of GLP-1RA in relation to insulin (p < 0.0001). Hypoglycaemia rates were low and not significantly different between cohorts. Conclusions: Combining BIAsp 30 + GLP-1RA provides glycaemic control with no significant difference to that of propensity score-matched people receiving basal insulin+GLP-1RA, with no increase in hypoglycaemia risk or weight gain.
KW - biphasic insulin aspart 30
KW - glucagon-like peptide-1 receptor agonist
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85179320062&partnerID=8YFLogxK
U2 - 10.1111/dme.15267
DO - 10.1111/dme.15267
M3 - Article
AN - SCOPUS:85179320062
SN - 0742-3071
VL - 41
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 5
M1 - e15267
ER -